BRAF and Hyperkeratosis: Vemurafenib, the first introduced BRAF inhibitor drug, was associated with a multitude of cAEs, including rash, increased sensitivity to ultraviolet rays, palmar-plantar erythro-dysesthesia (“hand-foot syndrome”), alopecia, itching, keratosis pilaris-like manifestations and hyperkeratosis [17,18,19,20,21,22,23,24].